Review Article
The Current State of Targeted Agents in Rectal Cancer
Table 4
Clinical trials of cetuximab in preoperative treatment of rectal cancer.
| Author | Phase | Study design(regimen) | N | RT dose (Gy) | pCR rate | Diarrhea (≥ G 3) | Reference |
| Kuo | I | 5FU+ cetuximab | 20 | 50.4 | 2/17(12%) | 2/20(10%) | [67] | Bertolini | I | Caplri + cetuximab | 20 | 50.4 | 5/20(25%) | 2/10(20%) | [68] | Velenik | I/II | Capecitabine + cetuximab | 40 | 45 | 2/40(5%) | 6/40(15%) | [69] | Horisberger | I/II | CAPOX + cetuximab | 48 | 50.4 | 4/48(8%) | 9/48(19%) | [70] | Chang | II | Cetuximab then 5FU + cetux | 40 | 50.4 | 3/40(7.5%) | 3/40(7.5%) | [71] | Rodel | II | Capecitabine + cetuximab | 37 | 45 | 3/37(8.1%) | 4/37(11%) | [72] | Oncofacts.com | II | Caplri + cetuximab | 50 | 50.4 | 4/50(8%) | 15/50(30%) | [44] |
|
|
RT:Radiotherapy, pCR: Pathological complete response.
|